These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1713346)

  • 1. Correlation of serum interferon with some clinical and humoral signs of systemic lupus erythematosus.
    Matei I; Ghyka G; Savi I; Tudor A
    Med Interne; 1990; 28(4):289-94. PubMed ID: 1713346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of serum interferon level in systemic lupus erythematosus.
    Ghyka G; Matei I; Savi I
    Med Interne; 1987; 25(4):239-43. PubMed ID: 2447630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Circulating interferon in patients with systemic lupus erythematosus. A prospective study].
    Dudli C; Kaiser V; Aguet M; Joller H; Pichler WI; Grob PJ; Fontana A
    Schweiz Med Wochenschr; 1986 Jan; 116(4):104-9. PubMed ID: 2419975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon and natural killer cells in systemic lupus erythematosus.
    Strannegård O; Hermodsson S; Westberg G
    Clin Exp Immunol; 1982 Nov; 50(2):246-52. PubMed ID: 6185256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons and systemic lupus erythematosus.
    Bankhurst AD
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():63-7. PubMed ID: 2441046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immunological characterization of systemic lupus erythematosus in patients with circulating interferon and migration inhibitory factor.
    Rovenský J; Bosák V; Zitnan D; Lackovic V; Borecký L; Pekárek J; Svejcar J; Lukác J; Matoková M
    Int J Clin Pharmacol Res; 1984; 4(6):465-8. PubMed ID: 6085328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.
    Landolt-Marticorena C; Bonventi G; Lubovich A; Ferguson C; Unnithan T; Su J; Gladman DD; Urowitz M; Fortin PR; Wither J
    Ann Rheum Dis; 2009 Sep; 68(9):1440-6. PubMed ID: 18772188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon-inducible genes lymphocyte antigen 6 complex E and tetratricopeptide repeats 1 are correlated with clinical features of patients with systemic lupus erythematosus].
    Tang JP; Gu YY; Shen N; Ye S; Qian J; Hua J; Chen XG; Chen SL; Bao CD; Wang Y; Zhang W
    Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1157-60. PubMed ID: 15387975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity.
    Robak E; Niewiadomska H; Robak T; Bartkowiak J; Błoński JZ; Woźniacka A; Pomorski L; Sysa-Jedrezejowska A
    Mediators Inflamm; 2001 Aug; 10(4):179-89. PubMed ID: 11577994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of the spontaneous humoral immunity reactions to collagen type I in systemic lupus erythematosus patients].
    Nesvizhskiĭ IuV; Solov'ev SK; Panasiuk AF
    Ter Arkh; 1986; 58(12):84-7. PubMed ID: 3824222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus].
    Francioni C; Fioravanti A; Gelli R; Megale F; Marcolongo R
    Recenti Prog Med; 1993 Oct; 84(10):679-86. PubMed ID: 8235034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.
    López P; Gómez J; Prado C; Gutiérrez C; Suárez A
    J Rheumatol; 2008 Aug; 35(8):1559-66. PubMed ID: 18597405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of natural killer cell activity by serum from patients with systemic lupus erythematosus: roles of disease activity and serum interferon.
    Ytterberg SR; Schnitzer TJ
    Ann Rheum Dis; 1984 Jun; 43(3):457-61. PubMed ID: 6204601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.
    Jacobi AM; Odendahl M; Reiter K; Bruns A; Burmester GR; Radbruch A; Valet G; Lipsky PE; Dörner T
    Arthritis Rheum; 2003 May; 48(5):1332-42. PubMed ID: 12746906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
    Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
    J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
    Schwarting A; Paul K; Tschirner S; Menke J; Hansen T; Brenner W; Kelley VR; Relle M; Galle PR
    J Am Soc Nephrol; 2005 Nov; 16(11):3264-72. PubMed ID: 16221871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus.
    Robak E; Smolewski P; Wozniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2004; 15(3):222-30. PubMed ID: 15542447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.